Please go to the PowerPak homepage
and select a course.
Evolving Strategies in Chronic Lymphocytic Leukemia Management
Updates for Specialty and Managed Care Pharmacists
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from AbbVie and BeiGene.
Registration & Dates for Activities
Thursday, September 21, 2023
2:30 - 3:45 PM ET Thursday, September 28, 2023
2:30 – 3:45 PM ET
Ryan J. Daley, PharmD, BCOP
Clinical Pharmacy Specialist, Leukemia
Memorial Sloan Kettering Cancer Center
New York, NY
Dr. Daley has disclosed that he services as a consultant for Da Volterra (Paris, France) and owns stock in Aprea Therapeutics Inc.
The clinical reviewer, Megan May, PharmD, BCOP has no relevant affiliations or financial relationships with a commercial interest to disclose.
Susanne Batesko, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.25 hours (0.125 ceu)
Estimated time to complete activity: 75 minutes
Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information: There is no fee for this educational activity.
Type of Activity: Application
Managed care and Specialty pharmacists
HOW TO EARN CREDIT
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live event; and 3) complete the posttest and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.
The goal of this educational activity is to improve managed care and specialty pharmacists' ability to recognize appropriate therapeutic selection and sequencing, the need to incorporate new agents and combinations into routine clinical practice, optimize adherence to oral agents, and minimize the severity and frequency of treatment-related adverse events tied to therapy to enhance patients with CLL quality of life and outcomes.
Upon completion of this activity, the participant should be better able to:
- Describe prognostic biomarkers and other clinical features that can clarify initial therapy selection and sequencing in subsequent treatment lines
- Assess the efficacy and tolerability of newly approved agents and novel combination regimens for elderly and high-risk patients with CLL
- Formulate care strategies that address adverse events and optimizes adherence with oral oncolytics indicated for CLL
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, AbbVie or BeiGene. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.